In a little over two 60 days, the date Canadian cannabis investors have long been waiting for will finally be here. On October 17, recreational marijuana will officially go on sale in in the country, which follows the passage of the Cannabis Act in June. Canada will become the first industrialized country in the world to allow adults to legally purchase marijuana.
With Canada emerging as a global powerhouse for cannabis cultivation, production, and trade (for now), investors are looking to Canadian marijuana stocks to boost portfolios. Pure Global Cannabis Inc. (PRCNF)(PURE) is a unique marijuana company that is working to take its own leading role within the industry.
The marijuana market has offered investors a new opportunity for what many are calling “the green rush”. But not every marijuana stock will be a smart investment as some are already finding out during these early days of growth. A new trend that investors are looking at is one of strategic investments as well as unique deals involving supply or product sales funnels.
The Path Is Clear
For Pure Global, that path is already being walked. This month the company announced that it had signed a letter of intent with another publicly traded marijuana company, Isodiol International Inc. (ISOLF)(ISOL). The agreement calls for ongoing supply of pharmaceutical and nutraceutical grade CBD isolates. It also will potentially include supply of other products.
Being that Isodiol is a global CBD innovator specializing in hemp-based health and wellness products, this agreement opens the door for both companies to not only collaborate on a supply of CBD for Isodiol but also allows for additional exploration into other areas of collaboration.
In fact, Pure’s President & CEO stated that the company is “excited to secure this pharmaceutical grade source of U.K. manufactured CBD from Isodiol and BSPG Labs at a time when new local British and regional European opportunities are presenting themselves by the day.”
As a GMP certified facility, Isodiol’s subsidiary BSPG Laboratories Ltd. has received government approval from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for the manufacturing of CBD under certificate number: UK API 48727.
Not A One Trick Pony
This isn’t the only path that Pure is exploring right now either. As the cannabis industry continues to remain fragmented, Pure Global is seizing new opportunities with a multitude of companies and entering into a number of other supply agreements.
The company has also signed definitive Supply Agreements with The Supreme Cannabis Company, Inc. (SPRWF)(FIRE) and two other reputable Access to Cannabis for Medical Purposes Regulations Licensed Producers. PureSinse, a wholly owned subsidiary of Pure Global Cannabis has purchased various quantities of premium quality medical cannabis that meet the high-quality standard requirements of PURE.
The company itself even points out that these Agreements represent a significant milestone for PureSinse, as it has now received the necessary product required to obtain a Sales License under the ACMPR, which is expected this quarter.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and Pure Global Cannabis, Midam is being paid a total of $90,000 from the company and ZERO shares of Pure Global Cannabis for a duration beginning July 23, 2018 and ending October 23, 2018. We may buy or sell additional shares of (PRCNF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Pure Global Cannabis.